Aileron Therapeutics, Inc. filed its 10-K on Mar 20, 2023 for the period ending Dec 31, 2022. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | -0.31% | -8.83% | +4.97% |
May. 16 | Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
May. 16 | Aileron Therapeutics, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.97% | 67.65M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.61% | 21.96B | |
-8.65% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Aileron Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt